This trial is still ongoing to assess safety, PK, pharmacodynamics, and efficacy (NCT02074839).50,199,200 A phase Ib/II study is ongoing to look at the combination of oral ivosidenib and subcutaneous azacitidine for newly diagnosed untreated AML patients with IDH1 mutations who were ineligible for intensive chemotherapy. Here, IDH1 is linked to acute myeloid leukemia.